We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Editorial: anti- TNF therapy and myopenia in Crohn's disease-another step towards personalised medicine. Authors' reply.
- Authors
Ding, N. S.; Malietzis, G.; Hart, A. L.
- Abstract
The authors respond to the insightful review of their retrospective study that examines the body composition parameters in relation to the outcomes of anti-tumor necrosis factor (TNF) therapy. They agree with C.D. Murray's assessment on limited causality for myopenia due to lack of anti-TNF levels. The authors think that the impact of muscle mass on outcomes in Crohn's disease may be explained by the administration and anti-inflammatory properties of infliximab.
- Subjects
TUMOR necrosis factors; BODY composition; INFLAMMATORY bowel disease treatment; MUSCLE mass; INFLIXIMAB; TUMOR treatment
- Publication
Alimentary Pharmacology & Therapeutics, 2018, Vol 47, Issue 1, p142
- ISSN
0269-2813
- Publication type
Editorial
- DOI
10.1111/apt.14409